Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8145779 | 1.00 | OPRD1 (0.40) | OPRD1OPRM1HSP90AA1HSP90AB1OPRK1 | |
| SCHEMBL4575462 | 1.00 | OPRD1 (0.40) | OPRD1OPRM1HSP90AA1HSP90AB1OPRK1 | |
| SCHEMBL8004084 | 0.84 | OPRD1 (0.37) | OPRD1OPRM1HSP90AA1HSP90AB1OPRK1 | |
| SCHEMBL6918646 | 0.82 | CYP1A2 (0.47) | OPRD1OPRM1OPRK1HPGDCYP1A2 | |
| SCHEMBL6937908 | 0.82 | GAA (0.35) | OPRD1HPGDALDH1A1MAPT | |
| SCHEMBL7993545 | 0.80 | CYP3A4 (0.54) | OPRD1OPRM1OPRK1HPGDCYP1A2 | |
| SCHEMBL8009424 | 0.80 | CYP3A4 (0.54) | OPRD1OPRM1OPRK1HPGDCYP1A2 | |
| SCHEMBL4591245 | 0.80 | CYP3A4 (0.54) | OPRD1OPRM1OPRK1HPGDCYP1A2 | |
| SCHEMBL8002856 | 0.80 | CYP3A4 (0.54) | OPRD1OPRM1OPRK1HPGDCYP1A2 | |
| SCHEMBL6246739 | 0.75 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1HPGDCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2021-07-22 | — | — | US | disclosed |
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | VERSI GROUP, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2019-02-07 | — | — | US | disclosed |
| EP-3436013-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Versi Group, LLC (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2017-10-12 | — | — | US | disclosed |
| WO-2017173067-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | VERSI GROUP, LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| US-8642599-B2 | Method of treating Parkinson's Disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity | VERSI GROUP, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20070066625-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2007-03-22 | — | — | US | disclosed |
| WO-2007027987-A2 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | MOUNT COOK BIOSCIENCES, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885HSP90AA1 3996/4885 |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885HSP90AA1 2968/4885 |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885HSP90AA1 3996/4885 |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885HSP90AA1 2968/4885 |
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885HSP90AA1 3983/4885 |
| US-20070066625-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885HSP90AA1 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.